Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray

World Journal of Gastroenterology

Volumn 13, Issue 5, 2007, Pages 699-708

  Chen, Wei Chang ^a   Lin, Mao Song ^b   Zhang, Bao Feng ^c   Fang, Jing ^c   Zhou, Qiong ^c   Hu, Ying ^c   Gao, Heng Jun ^c  

^a SOOCHOW UNIVERSITY   (China)

^b Tai Zhou People's Hospital   (China)

^c Key Laboratory of Health and Disease Genomics   (China)

Author keywords

Colon cancer; Immunohistochemistry; Tissue microarray

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; FORMALDEHYDE; MYC PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CHI SQUARE TEST; COLON CANCER; COLON CARCINOGENESIS; COLON CARCINOMA; COLON MUCOSA; COLON POLYPOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 33846963533     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i5.699     Document Type: Article

References (44)

1. Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000; 47: 57-70
2. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987; 238: 193-197
3. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-662
4. Serrano R, Gómez M, Farre X, Méndez M, De La Haba J, Morales R, Sanchez L, Barneto I, Aranda E. Tissue microarrays (TMAS) in colorectal cancer: Study of clinical and molecular markers. ASCO Meeting Abstracts 2004; 22: 9665
5. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000; 119: 854-865
6. Hao X, Tomlinson I, Ilyas M, Palazzo JP, Talbot IC. Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch 1997; 431: 167-172
7. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512
8. Kim JY, Lim SJ, Park K. Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays. Appl Immunohistochem Mol Morphol 2004; 12: 67-70
9. Messinetti S, Giacomelli L, Fabrizio G, Giarnieri E, Gabatel R, Manno A, Feroci D, Guerriero G, Masci E, Vecchione A. CD44v6 and Nm23-H1 protein expression related to clinicopathological parameters in colorectal cancer. Ann Ital Chir 2003; 74: 45-51
10. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, Aaltonen LA, Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002; 161: 439-447
11. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23: 201-205
12. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94: 3127-3134
13. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390
14. Weng L, Brown J, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001; 10: 237-242
15. Wong NA, Pignatelli M. Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 389-401
16. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-2645
17. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311
18. Martinez JA, Prevot S, Nordlinger B, Nguyen TM, Lacarriere Y, Munier A, Lascu I, Vaillant JC, Capeau J, Lacombe ML. Over-expression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut 1995; 37: 712-720
19. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000; 31: 406-414
20. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966-1975
21. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G. High-throughput tissue microarray analysis of cyclin E gene amplification and over-expression in urinary bladder cancer. Am J Pathol 2000; 157: 787-794
22. Lynch HT, Smyrk TC. Identifying hereditary nonpolyposis colorectal cancer. N Engl J Med 1998; 338: 1537-1538
23. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847
25. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan W, Lewis JJ, Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001; 158: 1245-1251
26. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-560
27. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825
28. Lu Y, Yamagishi N, Yagi T, Takebe H. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 1998; 16: 705-712
29. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419
30. Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosari S. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. J Pathol 1999; 187: 302-307
31. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823-4826
32. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97: 1037-1041
33. Zeng ZS, Hsu S, Zhang ZF, Cohen AM, Enker WE, Turnbull AA, Guillem JG. High level of Nm23-H1 gene expression is associated with local colorectal cancer progression not with metastases. Br J Cancer 1994; 70: 1025-1030
34. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033-1038
35. Smith DR, Myint T, Goh HS. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 1993; 68: 407-413
36. Kobayashi M, Honma T, Matsuda Y, Suzuki Y, Narisawa R, Ajioka Y, Asakura H. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 2000; 82: 1689-1693
37. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000; 21: 1935-1940
38. Gunther K, Brabletz T, Kraus C, Dworak O, Reymond MA, Jung A, Hohenberger W, Kirchner T, Kockerling F, Ballhausen WG. Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer. Dis Colon Rectum 1998; 41: 1256-1261
39. Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999; 80: 1046-1051
40. Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, Moriya Y, Hirohashi S. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 2000; 59: 302-309
41. Masramon L, Arribas R, Tortola S, Perucho M, Peinado MA. Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer. Br J Cancer 1998; 77: 2349-2356
42. Khor TO, Gul YA, Ithnin H, Seow HT. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma. Cancer Lett 2004; 210: 139-150
43. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39
44. Taniyama K, Goodison S, Ito R, Bookstein R, Miyoshi N, Tahara E, Tarin D, Urquidi V. PTEN expression is maintained in sporadic colorectal tumours. J Pathol 2001; 194: 341-348